Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782706 | 0.94 | IL2 (0.41) | IL2TRPV1HDAC6ALDH1A1ABL1 | |
| SCHEMBL615171 | 0.93 | HTR1F (0.41) | IL2TRPV1HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL1784219 | 0.93 | STIM1 (0.39) | IL2TRPV1HDAC6ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL615236 | 0.92 | HTR1F (0.40) | IL2TRPV1HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL1782601 | 0.91 | TP53 (0.40) | TRPV1HDAC6ALDH1A1TP53NPC1 | |
| SCHEMBL3374258 | 0.88 | IL2 (0.40) | IL2TRPV1HDAC6 | |
| SCHEMBL1782064 | 0.88 | TRPV1 (0.39) | IL2TRPV1HDAC6ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1782166 | 0.87 | IL2 (0.39) | IL2TRPV1HDAC6 | |
| SCHEMBL7922608 | 0.87 | IL2 (0.43) | IL2TRPV1HDAC6NPC1RAB9A | |
| SCHEMBL1782641 | 0.86 | TRPV1 (0.38) | IL2TRPV1HDAC6ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | IL2 5/4885TRPV1 111/4885HDAC6 161/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885TRPV1 92/4885HDAC6 230/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885TRPV1 92/4885HDAC6 230/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885TRPV1 92/4885HDAC6 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.